The great debate: are CTCs ready for prime time?

被引:1
作者
Samson, Susan [1 ]
Baas, Carole [2 ]
机构
[1] Univ Calif San Francisco, Helen Diller Comprehens Canc Ctr, Breast Oncol Program, Breast Sci Advocacy Core, San Francisco, CA 94143 USA
[2] NCI, Off Advocacy Relat, Bethesda, MD 20892 USA
来源
CONVERGENT SCIENCE PHYSICAL ONCOLOGY | 2015年 / 1卷 / 01期
关键词
cancer; circulating tumor cells; prostate cancer; bevacizumab; convergent science; patient advocacy;
D O I
10.1088/2057-1739/1/1/017001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页数:1
相关论文
共 5 条
  • [1] The Contribution of Angiogenesis to the Process of Metastasis
    Bielenberg, Diane R.
    Zetter, Bruce R.
    [J]. CANCER JOURNAL, 2015, 21 (04) : 267 - 273
  • [2] FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
  • [3] Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
    Montero, Alberto J.
    Escobar, Mauricio
    Lopes, Gilberto
    Glueck, Stefan
    Vogel, Charles
    [J]. CURRENT ONCOLOGY REPORTS, 2012, 14 (01) : 1 - 11
  • [4] Stevenson CE, 2012, FUTURE ONCOL, V8, P403, DOI [10.2217/FON.12.22, 10.2217/fon.12.22]
  • [5] Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
    Turley, Ryan S.
    Fontanella, Andrew N.
    Padussis, James C.
    Toshimitsu, Hiroaki
    Tokuhisa, Yoshihiro
    Cho, Eugenia H.
    Hanna, Gabi
    Beasley, Georgia M.
    Augustine, Christina K.
    Dewhirst, Mark W.
    Tyler, Douglas S.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3328 - 3339